• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


243.7000 DKK 8.3000 3.53%

As of 07:05:29 ET on 10/21/2014.

Snapshot for Genmab A/S (GEN)

Open: 235.1000 Day's Range: 232.5000 - 244.3000 Volume: 140,534
Previous Close: 235.4000 52wk Range: 180.1000 - 260.0000 1-Yr Rtn: -2.88%

Stock Chart for GEN

No chart data available.
  • GEN:DC 244.0000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 90.4206
Estimated P/E(12/2014) 61.1553
Relative P/E vs. KFX 4.3598
Earnings Per Share (DKK) (ttm) 2.6344
Est. EPS (DKK) (12/2014) 3.8950
Est. PEG Ratio 1.3786
Market Cap (M DKK) 13,534.83
Shares Outstanding (M) 56.82
30 Day Average Volume 193,678
Price/Book (mrq) 7.8761
Price/Sale (ttm) 17.6769
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil